For personal use only
Memphasys Limited
Half Year Report
31 December 2021
Appendix 4D | ||||||||||
Half year report | ||||||||||
Name of the entity: | Memphasys Limited | |||||||||
ABN: | 33 120 047 556 | |||||||||
Half year ended | Half year ended | |||||||||
('current period') | ('previous corresponding period') | |||||||||
31 December 2021 | 31 December 2020 | |||||||||
Results for announcement to the market | ||||||||||
$A'000 | ||||||||||
Sales from continuing operations | Up | from 0 | to | 14 | ||||||
Gross profit (loss) from continuing operations | Up | from 0 | to | 5 | ||||||
Profit (loss) from continuing activities after tax | Up | 30% | to | (938) | ||||||
attributable to members | ||||||||||
Net Profit (loss) for the period attributable to | Up | 30% | at | (938) | ||||||
members | ||||||||||
Dividends (distributions) | Amount per security Franked amount per | |||||||||
security | ||||||||||
Final dividend | Nil | Nil | ||||||||
Previous corresponding period | Nil | Nil | ||||||||
Record date for determining entitlements to the
dividend,N/A Brief explanation of any of the figures reported above:
Refer to "Principal Activities and review of operations in the directors report attached to the Appendix 4D"
NTA backing | 31 December 2021 | 31 December 2020 |
Net tangible asset backing per ordinary security | (0.0026) dollars | 0.001 dollars |
31 December 2021 | Appendix 4D |
For personal use only
Memphasys Limited
Half Year Report
31 December 2021
Audit/Review Status
This report is based on accounts to which one of the following applies:(Tick one)
The accounts have been audited | The accounts have been subject to review | X |
The accounts are in the process of being | The accounts have not yet been audited or | |
audited or subject to review | reviewed | |
If the accounts have not yet been audited or subject to review and are likely to be subject to dispute or qualification, a description of the likely dispute or qualification:
The review report is an unqualified review opinion
31 December 2021 | Appendix 4D |
For personal use only
Memphasys Limited
and its Controlled Entities ABN 33 120 047 556
Interim Financial Report
for the half-year ended 31 December 2021
For personal use only
Memphasys Limited and its Controlled Entities
Financial report 31 December 2021
Contents
Directors' Report | 3 |
Consolidated Statement of Profit or Loss and Other Comprehensive Income | 9 |
Consolidated Statement of Financial Position | 10 |
Consolidated Statement of Changes in Equity | 11 |
Consolidated Statement of Cash Flows | 12 |
Notes to the Consolidated Interim Financial Statements | 13 |
Directors' Declaration | 19 |
Auditor's Independence Declaration | 20 |
Independent Auditor's Review Report to the Members of Memphasys Limited | 21 - 22 |
Corporate Directory | 23 |
2
For personal use only
Memphasys Limited and its Controlled Entities
Directors' Report
The Directors submit their report for the consolidated entity consisting of Memphasys Limited ("the Company") and its controlled entities ("MEM" or the "Group") for the half-year ended 31 December 2021.
Directors
The names of the Directors of the Company in office at any time during or since the end of the interim period are:
Ms Alison Coutts | Executive Chairman |
Mr Andrew Goodall | Non-Executive Director |
Mr Shane Hartwig | Independent Non-Executive Director |
Mr Paul Wright | Independent Non-Executive Director |
REVIEW OF OPERATIONS
Memphasys has made sound progress in the past 6 months, with the Company transitioning with its FelixTM system from product development to commencing commercial sales. FelixTM is a novel automated device for quickly and gently separating high quality sperm from a raw semen sample for use in human IVF procedures. The result comes despite continued difficulties caused by COVID-19 to supply chains and to the global slowdown and temporary shutting of IVF clinics.
Commencement of FelixTM Sales for Clinical Use
During the half-year period, Memphasys completed its first clinical sale of its FelixTM System to the Coimbatore Womens Hospital Centre in India, one of the 13 international participants in the Felix™ system Key Opinion Leader ("KOL") in vitro study.
This sale comprised a FelixTM desktop console, and an initial supply of sterile Felix single-use cartridges used to quickly process a semen sample and separate out the best sperm cells.
The Coimbatore Womens Hospital will initially utilise the Felix™ system for couples where the male has demonstrated potential signs of below average sperm quality (low sperm concentration, poor motility, high DNA damage or poor morphology), which according to the Centre represents almost half of male semen samples they deal with. Their male fertility (andrology) laboratory is a regional reference centre in Tamil Nadhu.
Memphasys believes the Coimbatore sale has a strong strategic significance, with India representing one of four 'early markets' for the Felix™ system. The Indian market is sizable, accounting for approximately 10% of the global demand for fresh IVF cycles1.
In 2017, approximately 190,000 IVF cycles were performed in India. This number is forecast to rise to 587,570 by 2025.
Sale of Felix for Research Application
Memphasys also completed its first sale of a FelixTM system for research use with a sale to Anhui Women & Children's Hospital in China, a national leader in male infertility research.
The sale was made by Memphasys' China distributor, Diagens Biotechnology Company Ltd ("Diagens").
Diagens is a Chinese company that manufactures and distributes proprietary and other products to its network of 500+ assisted reproduction centres and 300+ prenatal diagnosis centres in China. Memphasys has been collaborating with Diagens for the past 18 months.
Diagens is working with Memphasys to prepare a submission to China's National Medical Products Administration (NMPA) - the medical regulatory authority in China - on a potential fast track "Green Channel"
- Allied Market Research Report, 2019
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Memphasys Ltd. published this content on 25 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2022 07:41:07 UTC.